Navigation Links
M3-Wake Research Partners with EmergeOrtho to Create M3-Emerging Medical Research
Date:11/13/2018

M3 Wake Research Associates, among the nation’s largest Phase I-IV clinical trial site service companies in North America, announces a new partnership with EmergeOrtho, one of the largest physician-owned orthopedic practices in North Carolina, and a leading provider of innovative, quality, comprehensive musculoskeletal care. This new joint venture will form M3-Emerging Medical Research, expanding Wake Research’s coast-to-coast coverage of clinical research populations in the United States and incorporating communities of nearly 20 million people.

“Clinical research like this allows patients to have access to new treatments that may be otherwise unavailable, and advances the care of all patients,” stated David Musante, M.D., spine surgeon at EmergeOrtho. “EmergeOrtho and Wake Research both have an established, successful track record of performing cutting-edge clinical research. Combining forces as M3-Emerging Medical Research will enable us to provide even greater opportunities for our patients’ health.”

M3-Wake Research was originally founded by a large multi-specialty group practice and has conducted clinical research studies since 1984. Based in the Research Triangle Park area of Raleigh, NC, Wake Research has built a combined database of more than 950,000 subjects to date, within an integrated network of 15 research sites operating in seven states: Alabama, Arizona, California, Georgia, North Carolina, Tennessee, and Texas. Their board-certified physicians have completed more than 6,000 successful clinical trials in most major therapeutic areas, with particular expertise in gastroenterology, neuroscience, dermatology, endocrinology, immunology, and women’s health.

EmergeOrtho’s team includes more than 100 orthopedic specialty physicians serving patients from 49 locations and across 21 counties in North Carolina. Emerging Medical Research will be integrated as part of M3-Wake Research’s network, and will benefit from M3 Wake’s industry-leading infrastructure including centralized patient recruitment and retention, company-wide QA/QC program, an in-house training program, and marketing and advertising services.

“This exciting partnership brings one of the largest and most established, highly successful physician-owned orthopedic practices in the region into our nationwide research network,” stated Ella Grach, MD, President and Chief Executive Officer of Wake Research. “The EmergeOrtho team has built a strong operation offering an advanced expertise in all subspecialties related to conditions of the bones, muscles, and joints. With its reputation for being patient-focused, and as the ‘go-to practice’ for orthopedic care and research, EmergeOrtho will be a key part of our continued research network expansion,” Dr. Grach continued. “Together, we will continue meeting the evolving needs of the drug discovery process and closing the gap between clinical research and healthcare by offering clinical trials as a care option.”

As a result of this joint venture, Emerging Medical Research joins the family of M3 USA brands including MDLinx, a clinical education and medical news website, The Medicus Firm, a physician and advanced practitioner recruiting firm, and PracticeMatch, which provides healthcare employers with the nation’s largest physician recruitment marketing resource. No further financial details of the transaction were made publicly available at this time.

About M3 Inc.:
M3 Inc. operates in the US, Asia, and Europe with over 4 million physician members globally via its physician websites such as mdlinx.com, m3.com, research.m3.com, doctors.net.uk, medigate.net and medlive.cn. M3 Inc. is a publicly traded company on the Tokyo Stock Exchange (TYO:2413) with subsidiaries in major markets including USA, UK, Japan, S. Korea, and China. M3 Inc. provides services to healthcare and the life science industry. In addition to market research, these services include medical education, ethical drug promotion, clinical development, job recruitment, and clinic appointment services. M3 has offices in Tokyo, Washington D.C., Fort Washington, PA, Oxford, London, Beijing, and Seoul.

About M3-Wake Research, Inc.:
M3-Wake Research is an organization of integrated investigational sites, committed to excellence, working closely with and meeting the needs of the biopharmaceutical, biotechnology, medical device and pharmaceutical industries. M3-Wake Research’s 15 sites are fully equipped to meet the needs of sponsors and CROs in the conduct of Phase I-IV clinical trials in a large variety of indications.

M3-Wake Research is known for effectively combining strategic volunteer recruitment, rapid trial start-up and subject enrollment/retention with high quality clinical trial conduct, using standardized operating procedures and centralized marketing and advertising to ensure rapid subject enrollment. M3-Wake Research sites have conducted more than 6,000 research studies for hundreds of pharmaceutical and biotech sponsors and CROs. Wake Research’s mission is to bring novel medications, biologics and device through clinical research to as many people as possible while providing unparalleled service and exceptional value to clinical trial partners and stakeholders. Media contact: Cameron Knowles, Director of Advertising & Marketing – cknowles(at)wakeresearch(dot)com. 919.781.2514

About Emerge Ortho: In 2016, four of the state’s top orthopedic practices teamed up to provide the highest level of patient-centered care, delivered in a convenient, efficient and cost-effective manner. Now serving patients with 49 offices in 21 counties from the mountains to the coast, EmergeOrtho is one of the largest physician-owned orthopedic practices in North Carolina.

Statewide, EmergeOrtho’s medical team includes well over 100 highly trained orthopedic specialty physicians and nearly as many mid-level providers. This unparalleled team offers advanced expertise in all subspecialties dealing with conditions of the bones, muscles and joints, as well as unmatched resources through collaboration with other specialists in the practice.

Read the full story at https://www.prweb.com/releases/m3_wake_research_partners_with_emergeortho_to_create_m3_emerging_medical_research/prweb15898206.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology news :

1. Large animal models of Huntingtons disease offer new and promising research options
2. Penn State Hass avocado research poster wins American Society For Nutrition Annual Awards
3. New research examines connection between inflammatory stimulus and Parkinsons disease
4. New research points to benefits of eggs, even for those at cardiovascular risk
5. Scientists awarded $5.5 million for wheat, rice blast research
6. Cleveland Clinic research shows gut bacteria byproduct predicts heart attack and stroke
7. CNIO researchers capture the replication of the human genome for the first time
8. Researchers pinpoint how trees play role in smog production
9. New research projects to enhance bioinformatics and computational biology tools and methodologies
10. Research spinoff ReXceptor gets license for Alzheimers treatment
11. Huddersfield researchers publish a book exploring the link between evolution and criminal behavior
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2019)... ... July 17, 2019 , ... ... the Southeast, and its acclaimed pediatric urologists are among the professionals honored ... annual recognition signifies excellence among the country’s pediatric healthcare landscape. , Georgia ...
(Date:7/11/2019)... ... July 11, 2019 , ... ... Legionella DNA test, today announced a partnership with LiquiTech, a leader in ... this strategic partnership, LiquiTech will integrate Spartan’s innovative environmental DNA testing platform ...
(Date:7/9/2019)... Del. (PRWEB) , ... July 08, 2019 , ... ... Court ruled in favor of Danisco’s ownership of the innovation behind two Danisco ... that an entitlement action could be based on prior art was without merit ...
Breaking Biology News(10 mins):
(Date:5/31/2019)... ... ... For many years, the primary forms of cancer treatment have been chemotherapy, radiation and ... led to the advent of Chimeric Antigen Receptor T (CAR T) cell therapy, which ... The CAR enables the final product to produce chemicals in the hopes that the ...
(Date:5/31/2019)... (PRWEB) , ... May 30, 2019 , ... ... the first to demonstrate an efficient delivery system for the sustained release of ... The platelet-rich plasma-based gel system was able to deliver CM into the injured ...
(Date:5/15/2019)... RIVER FALLS, Wis. (PRWEB) , ... May 16, ... ... uniform oil and water mixtures. As a result, food and beverage products rely ... However, today, consumers demand more natural sounding label declarations. This paradigm shift triggers ...
(Date:5/7/2019)... ... May 06, 2019 , ... "The new Liquid Nitrogen ... repositories being asked to store cellular products being used in adoptive therapy ... are world leaders, who have shared their expertise in building and managing facilities ...
Breaking Biology Technology: